Search

everythinglearnresearchcommunity

for

Search:↓

Some drugs linked to growth hormones may increase the chance of hair loss in women.

RY-023, a specific drug, can improve early stage memory learning without affecting general activity in rats, but it's less effective for later learning stages and doesn't impact memory recall.

Finasteride and dutasteride are equally effective and safe for treating benign prostatic hyperplasia.

GLP-1 agonists may help treat certain skin conditions.

Certain histamine receptors (H2R, H3R, H4R) have unique roles in treating skin diseases, with H2R helping with chronic urticaria and other conditions, H3R providing pain relief and allergy benefits, and H4R reducing inflammation and itchiness.

TRH stimulates human hair growth and extends the hair growth phase.

Thyrotropin-releasing hormone may help control skin and hair growth and could aid in treating related disorders.

A new treatment for hair loss shows promise with fewer side effects.

Eplerenone, a mineralocorticoid receptor antagonist, was found to promote hair growth in human hair follicles.

Two new compounds can block androgen receptor activity in different ways and may lead to new treatments for androgen-related diseases.

Nitrendipine and nifedipine effectively block muscle contractions, while papaverine relaxes them and minoxidil needs high amounts to work.

HNG helps hair grow by keeping hair in the growth phase longer.

Neurosteroids may help treat disorders with too much dopamine activity.

Potassium channel openers show promise for treating heart disease and other conditions, but more research is needed to fully understand their effects and safety.

Agomelatine may help reduce benign prostatic hyperplasia by blocking certain inflammatory pathways.

Allergic rhinitis increases hair loss risk, but antihistamines can reduce it.

GLP-1 RAs help with diabetes and skin issues but can cause skin reactions and surgery challenges.

Allopregnanolone may enhance alcohol's effects on dopamine neurons, influencing addiction risk.

GLP-1 receptor agonists, like Dulaglutide, Liraglutide, and Semaglutide, have potential benefits beyond the pancreas, including neuroprotection, pain suppression, cardiovascular protection, obesity management, and cancer treatment, but there are concerns about pancreatitis and pancreatic cancer risks.

Different substances that activate or block the androgen receptor can affect male development and treat conditions like prostate cancer.

New nonsteroidal molecules can potentially increase dihydrotestosterone in neurons by blocking certain enzymes, without affecting prostate and seminal vesicle weight.

The nature of the side chain in RU 58841 derivatives greatly affects its AR affinity, with the N-(iodopropenyl) derivative 13 showing the highest AR binding affinity, suggesting its potential for developing high-affinity radioiodinated AR radioligands.

New drugs like clonidine and prazosin show promise for treating high blood pressure despite some side effects.

3α‐OH‐DHP is essential for reducing nerve activity related to blood pressure control during pregnancy.

GLP-1RA therapy may increase the risk of hair loss.

Gastric bypass surgery improved a woman's hormonal disorder without the need for medication.

Thyroid receptor β can help develop new drugs to treat hair loss.

Some skin medications can have harmful interactions with the COVID-19 drug nirmatrelvir-ritonavir, but not with molnupiravir.

Certain peptides can prevent hair loss in young rats caused by a cancer drug.

EGFR cancer drugs often cause a rash, which can lead to distress and isolation, but may also improve outcomes for some cancer patients. Current treatments for the rash are limited, but a compound called menadione shows promise.